Read by QxMD icon Read

Tumor Transferrin Imaging

Zheng Zhang, Jingrong Yang, Qingqing Min, Chenjie Ling, Debabrata Maiti, Jiaying Xu, Liqiang Qin, Kai Yang
Hypoxic microenvironments in the solid tumor play a negative role in radiotherapy. Holo-lactoferrin (holo-Lf) is a natural protein, which acts as a potential ligand of transferrin receptor (TfR). In this work, an anticancer drug, doxorubicin (Dox)-loaded liposome-holo-Lf nanocomposites, is developed for tumor targeting and imaging guided combined radiochemotherapy. Dox-loaded liposome-holo-Lf (Lf-Liposome-Dox) nanocomposites exhibit significant cellular uptake likely owing to the TfR receptor-mediated targeting accumulation of Lf-Liposome-Dox nanocomposites...
January 15, 2019: Small
Lin Cui, Yuli Wang, Meng Liang, Xiaoyang Chu, Shiyao Fu, Chunsheng Gao, Qianqian Liu, Wei Gong, Meiyan Yang, Zhiping Li, Lian Yu, Chunrong Yang, Zhide Su, Xiangyang Xie, Yang Yang, Chunsheng Gao
Therapeutic outcome for the treatment of glioma was often limited due to the two barriers involved: the blood-brain barrier (BBB) and blood-brain tumor barrier (BBTB). Therefore, the development of nanocarriers that possess both BBB and BBTB permeability and glioma-targeting ability is of great importance for the chemotherapy of glioma. New frontiers in nanomedicine are advancing the research of new biomaterials. Here we constructed a natural high-density lipoprotein particle (HDL)-based drug delivery system with the dual-modification of T7 and d A7R peptide ligand (T7/d A7R-HDL) to achieve the above goals...
November 2018: Drug Delivery
Spencer C Behr, Javier E Villanueva-Meyer, Yan Li, Yung-Hua Wang, Junnian Wei, Anna Moroz, Julia Kl Lee, Jeffrey C Hsiao, Kenneth T Gao, Wendy Ma, Soonmee Cha, David M Wilson, Youngho Seo, Sarah J Nelson, Susan M Chang, Michael J Evans
Noninvasive tools that target tumor cells could improve the management of glioma. Cancer generally has a high demand for Fe(III), an essential nutrient for a variety of biochemical processes. We tested whether 68Ga-citrate, an Fe(III) biomimetic that binds to apo-transferrin in blood, detects glioma in preclinical models and patients using hybrid PET/MRI. Mouse PET/CT studies showed that 68Ga-citrate accumulates in subcutaneous U87MG xenografts in a transferrin receptor-dependent fashion within 4 hours after injection...
November 2, 2018: JCI Insight
Qiankun Chen, Ji Liu
Aim: The aim of this study was to prepare transferrin (Tf) and folic acid (FA) co-modified bufalin (BF) liposomes for lung cancer treatment. Method: In this study, (FA+Tf) BF-LPs were prepared using the high-pressure homogenization method. Results: The EE% and DL% of prepared LPs were 82.3% and 10.7%, respectively, and the mean diameter was 120.4 nm from three batches. In vitro release showed that the release of BF from (FA+Tf) BF-LPs was slow with burst effects at an early stage...
2018: International Journal of Nanomedicine
Mingyue Xue, Jingjin Zhao, Zhihua Zhan, Shulin Zhao, Chuanqing Lan, Fanggui Ye, Hong Liang
Photodynamic therapy (PDT) is a non-invasive phototherapy that has gained significant attention for cancer therapy. However, image-guided PDT still remains a considerable challenge. Herein, we developed a targeted, near-infrared (NIR) fluorescence imaging nanoprobe for cancer cells by preparing natural biomass carbon dots (NBCDs) from lychee exocarp, and loading transferrin and a photosensitizer on the NBCD surfaces for image-guided PDT of cancer cells and mouse tumors. Because the surfaces of cancer cells exhibit more transferrin receptors, the proposed NIR fluorescent nanoprobe can better penetrate cancer cells for cancer cell targetable fluorescence imaging...
October 4, 2018: Nanoscale
Kelly E Henry, Megan M Dacek, Thomas R Dilling, Jonathan D Caen, Ian L Fox, Michael J Evans, Jason S Lewis
Purpose: Pancreatic ductal adenocarcinoma (PDAC) is one of the most deadly cancers, with a 5-year survival rate of less than 10%. Physicians often rely on biopsy or CT to guide treatment decisions, but these techniques fail to reliably measure the actions of therapeutic agents in PDAC. KRAS mutations are present in >90% of PDAC and are connected to many signaling pathways through its oncogenic cascade, including extracellular regulated kinase (ERK) and MYC. A key downstream event of MYC is transferrin receptor (TfR), which has been identified as a biomarker for cancer therapeutics and imaging...
September 18, 2018: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
Lorenzo Calisti, Matilde Cardoso Trabuco, Alberto Boffi, Claudia Testi, Linda Celeste Montemiglio, Amédée des Georges, Irene Benni, Andrea Ilari, Bartłomiej Taciak, Maciej Białasek, Tomasz Rygiel, Magdalena Król, Paola Baiocco, Alessandra Bonamore
Ferritin H-homopolymers have been extensively used as nanocarriers for diverse applications in the targeted delivery of drugs and imaging agents, due to their unique ability to bind the transferrin receptor (CD71), highly overexpressed in most tumor cells. In order to incorporate novel fluorescence imaging properties, we have fused a lanthanide binding tag (LBT) to the C-terminal end of mouse H-chain ferritin, HFt. The HFt-LBT possesses one high affinity Terbium binding site per each of the 24 subunits provided by six coordinating aminoacid side chains and a tryptophan residue in its close proximity and is thus endowed with strong FRET sensitization properties...
2018: PloS One
Yang Du, Kelong Fan, Hejun Zhang, Li Li, Peixia Wang, Jiuyang He, Shigang Ding, Xiyun Yan, Jie Tian
Optical imaging technologies improve clinical diagnostic accuracy of early gastric cancer (EGC). However, there was a lack of imaging agents exhibiting molecular specificity for EGCs. Here, we employed the dye labeled human heavy-chain ferritin (HFn) as imaging nanoprobe, which recognizes tumor biomarker transferrin receptor 1 (TfR1), to enable specific EGC imaging using confocal laser endomicroscopy (CLE). TfR1 expression was initially examined in vitro in gastric tumor cells and in vivo through whole-body fluorescence and CLE imaging in tumor-bearing mice...
October 2018: Nanomedicine: Nanotechnology, Biology, and Medicine
Alena Rudkouskaya, Nattawut Sinsuebphon, Jamie Ward, Kate Tubbesing, Xavier Intes, Margarida Barroso
Maintaining an intact tumor environment is critical for quantitation of receptor-ligand engagement in a targeted drug development pipeline. However, measuring receptor-ligand engagement in vivo and non-invasively in preclinical settings is extremely challenging. We found that quantitation of intracellular receptor-ligand binding can be achieved using whole-body macroscopic lifetime-based Förster Resonance Energy Transfer (FRET) imaging in intact, live animals bearing tumor xenografts. We determined that FRET levels report on ligand binding to transferrin receptors conversely to raw fluorescence intensity...
September 28, 2018: Journal of Controlled Release: Official Journal of the Controlled Release Society
Fred C Lam, Stephen W Morton, Jeffrey Wyckoff, Tu-Lan Vu Han, Mun Kyung Hwang, Amanda Maffa, Elena Balkanska-Sinclair, Michael B Yaffe, Scott R Floyd, Paula T Hammond
Effective treatment for glioblastoma (GBM) is limited by the presence of the blood-brain barrier (BBB) and rapid resistance to single agent therapies. To address these issues, we developed a transferrin-functionalized nanoparticle (Tf-NP) that can deliver dual combination therapies. Using intravital imaging, we show the ability of Tf-NPs to traverse intact BBB in mice as well as achieve direct tumor binding in two intracranial orthotopic models of GBM. Treatment of tumor-bearing mice with Tf-NPs loaded with temozolomide and the bromodomain inhibitor JQ1 leads to increased DNA damage and apoptosis that correlates with a 1...
May 18, 2018: Nature Communications
Yi Gou, Dandan Miao, Min Zhou, Lijuan Wang, Hongyu Zhou, Gaoxing Su
Over the past decade, more interests have been aroused in engineering protein-based nanoformulations for cancer treatment. This excitement originates from the success of FDA approved Abraxane (Albumin-based paclitaxel nanoparticles) in 2005. The new generation of biocompatible endogenous protein-based nanoformulations is currently constructed through delivering cancer therapeutic and diagnostic agents simultaneously, as named potential theranostics. Protein nanoformulations are commonly incorporated with dyes, contrast agents, drug payloads or inorganic nanoclusters, serving as imaging-guided combinatorial cancer therapeutics...
2018: Frontiers in Pharmacology
Shodai Takahashi, Yu Kagami, Kenjiro Hanaoka, Takuya Terai, Toru Komatsu, Tasuku Ueno, Masanobu Uchiyama, Ikuko Koyama-Honda, Noboru Mizushima, Tomohiko Taguchi, Hiroyuki Arai, Tetsuo Nagano, Yasuteru Urano
In biological systems, the pH in intracellular organelles or tissues is strictly regulated, and differences of pH are deeply related to key biological events such as protein degradation, intracellular trafficking, renal failure, and cancer. Ratiometric fluorescence imaging is useful for determination of precise pH values, but existing fluorescence probes have substantial limitations, such as inappropriate p Ka for imaging in the physiological pH range, inadequate photobleaching resistance, and insufficiently long excitation and emission wavelengths...
May 9, 2018: Journal of the American Chemical Society
Yalei Zhou, Jie Zhou, Feng Wang, Haifeng Yang
Particles which bear tumor cell targeting and multimode imaging capabilities are promising in tumor diagnosis and cancer therapy. A simple and versatile method to fabricate gold/polydopamine-Methylene Blue@Bovine Serum Albumin-glutaraldehyde-Transferrin composite particles (Au/PDA-MB@BSA-GA-Tf NPs) for tumor cell targeting and fluorescence (FL) / surface-enhanced Raman scattering (SERS) dual-modal imaging were reported in this work. Polydopamine (PDA) spheres played an important role in gold ion reduction, gold nanoparticle (Au NPs) binding and methylene blue (MB) adsorption, MB were employed as both fluorescence label and Raman reporter...
May 1, 2018: Talanta
Naruhiko Ikoma, Hiroharu Shinozaki, Akihito Kozuki, Sho Ibuki, Kokichi Sugano, Makio Mukai, Yoshihiro Masuda, Kenji Kobayashi, Yoshiro Ogata
Hereditary hemochromatosis (HH) is associated with an increased risk for hepatocellular carcinoma (HCC) occurring predominantly in patients with cirrhosis at the time of diagnosis. However, HCC in non-cirrhotic liver of patients with secondary hemochromatosis is rare. A 67-year-old man with a history of myelodysplastic syndrome (MDS) was found to have a liver tumor on abdominal computed tomography (CT). On the basis of findings of high levels of serum ferritin and transferrin saturation, and low intensity of liver parenchyma on magnetic resonance imaging (MRI), we made a diagnosis of hemochromatosis...
December 2013: World Journal of Oncology
Mingting Zhu, Zonghai Sheng, Yali Jia, Dehong Hu, Xin Liu, Xianyuan Xia, Chengbo Liu, Pan Wang, Xiaobing Wang, Hairong Zheng
Active-targeted cancer imaging and therapy of glioma has attracted much attention in theranostic nanomedicine. As a promising tumor-targeting ligand, holo-transferrin (holo-Tf) has been applied for enhancing delivery of nanotheranostics. However, holo-Tf-based nanoassemblies for active targeting mediated multimodal imaging and therapeutics have not been previously reported. Here, we develop a one-step method for the preparation of holo-Tf-indocyanine green (holo-Tf-ICG) nanoassemblies for fluorescence (FL) and photoacoustic (PA) dual-modal imaging and photothermal therapy (PTT) of glioma...
November 15, 2017: ACS Applied Materials & Interfaces
Kelly E Henry, Thomas R Dilling, Dalya Abdel-Atti, Kimberly J Edwards, Michael J Evans, Jason S Lewis
The current standard for breast PET imaging is 18 F-FDG. The heterogeneity of 18 F-FDG uptake in breast cancer limits its utility, varying greatly among receptor status, histopathologic subtypes, and proliferation markers. 18 F-FDG PET often exhibits nonspecific internalization and low specificity and sensitivity, especially with tumors smaller than 1 cm3 MYC is a protein involved in oncogenesis and is overexpressed in triple-negative breast cancer (TNBC). Increased surface expression of transferrin receptor (TfR) is a downstream event of MYC upregulation and has been validated as a clinically relevant target for molecular imaging...
January 2018: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
Jen-Chieh Tseng, Nara Narayanan, Guojie Ho, Kevin Groves, Jeannine Delaney, Bagna Bao, Jun Zhang, Jeffrey Morin, Sylvie Kossodo, Milind Rajopadhye, Jeffrey D Peterson
Physical measurement of tumor volume reduction is the most commonly used approach to assess tumor progression and treatment efficacy in mouse tumor models. However, it is relatively insensitive, and often requires long treatment courses to achieve gross physical tumor destruction. As alternatives, several non-invasive imaging methods such as bioluminescence imaging (BLI), fluorescence imaging (FLI) and positron emission tomography (PET) have been developed for more accurate measurement. As tumors have elevated glucose metabolism, 18F-fludeoxyglucose (18F-FDG) has become a sensitive PET imaging tracer for cancer detection, diagnosis, and efficacy assessment by measuring alterations in glucose metabolism...
2017: PloS One
Jeong-Hwan Kim, Haruki Eguchi, Yoshihiro Ishikawa
Ultrafine Au quantum clusters (QCs) were synthesized by etching host Au nanoparticles in the presence of ethylenediamine (en) and exhibited both strong photoluminescence (PL) and specific anticancer activity. The cutting-edge feature of this QC compound comprises subnanometer-size rhombohedral Au8 , which consists of 8 units of the anticancer motif, namely, an Au+ (en) complex (Au(en)QCs), which contributes to photo- and physicochemical stability as well as subcellular theranostic activity in intracellular PL imaging and in situ targeting...
July 6, 2017: Nanoscale
Rahul Aggarwal, Spencer C Behr, Pamela L Paris, Charles Truillet, Matthew F L Parker, Loc T Huynh, Junnian Wei, Byron Hann, Jack Youngren, Jiaoti Huang, Gayatri Premasekharan, Nimna Ranatunga, Emily Chang, Kenneth T Gao, Charles J Ryan, Eric J Small, Michael J Evans
Noninvasive biomarkers that detect the activity of important oncogenic drivers could significantly improve cancer diagnosis and management of treatment. The goal of this study was to determine whether 68 Ga-citrate (which avidly binds to circulating transferrin) can detect MYC-positive prostate cancer tumors, as the transferrin receptor is a direct MYC target gene. PET imaging paired with 68 Ga-citrate and molecular analysis of preclinical models, human cell-free DNA (cfDNA), and clinical biopsies were conducted to determine whether 68 Ga-citrate can detect MYC-positive prostate cancer...
September 2017: Molecular Cancer Research: MCR
Yang Zhao, Jing Peng, Jingjin Li, Ling Huang, Jinyi Yang, Kai Huang, Hewen Li, Ning Jiang, Shaokuan Zheng, Xuening Zhang, Yuanjie Niu, Gang Han
Biocompatibility, targeting, and clearance are key challenges in the design of new MRI contrast agents. Herein, we report on a tumor-targeting, gadolinium biomineralized human transferrin (Tf) protein-based nanoparticle (Gd@Tf NP) for MRI use. As compared to the conventionally used gadolinium chelates, the resultant Gd@Tf NPs possess outstanding chemical stability and exhibited superior longitudinal relaxation. More importantly, our MR images show that Gd@Tf indeed retained the natural tumor targeting ability and the subsequent tumor retrieval biofunctions of Tf...
July 12, 2017: Nano Letters
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"